ELVN PE Ratio & Valuation,Is ELVN Overvalued

ELVN Relative Valuation

ELVN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ELVN is overvalued; if below, it's undervalued.

Historical Valuation

Enliven Therapeutics Inc (ELVN) is now in the Fair zone, suggesting that its current forward PS ratio of 120553.71 is considered Fairly compared with the five-year average of -9.29. The fair price of Enliven Therapeutics Inc (ELVN) is between 6.58 to 21.26 according to relative valuation methord.

Relative Value

Fair Zone

6.58-21.26

Current Price：16.86

Fair

-9.59

-3.75

EV/EBITDA

Enliven Therapeutics Inc. (ELVN) has a current EV/EBITDA of -3.75. The 5-year average EV/EBITDA is -4.68. The thresholds are as follows: Strongly Undervalued below -9.49, Undervalued between -9.49 and -7.08, Fairly Valued between -2.27 and -7.08, Overvalued between -2.27 and 0.13, and Strongly Overvalued above 0.13. The current Forward EV/EBITDA of -3.75 falls within the Historic Trend Line -Fairly Valued range.

-4.23

EV/EBIT

Enliven Therapeutics Inc. (ELVN) has a current EV/EBIT of -4.23. The 5-year average EV/EBIT is -5.81. The thresholds are as follows: Strongly Undervalued below -10.55, Undervalued between -10.55 and -8.18, Fairly Valued between -3.44 and -8.18, Overvalued between -3.44 and -1.07, and Strongly Overvalued above -1.07. The current Forward EV/EBIT of -4.23 falls within the Historic Trend Line -Fairly Valued range.

120553.71

Enliven Therapeutics Inc. (ELVN) has a current PS of 120553.71. The 5-year average PS is 92182.13. The thresholds are as follows: Strongly Undervalued below -108398.24, Undervalued between -108398.24 and -8108.06, Fairly Valued between 192472.32 and -8108.06, Overvalued between 192472.32 and 292762.50, and Strongly Overvalued above 292762.50. The current Forward PS of 120553.71 falls within the Historic Trend Line -Fairly Valued range.

-11.50

P/OCF

Enliven Therapeutics Inc. (ELVN) has a current P/OCF of -11.50. The 5-year average P/OCF is -10.80. The thresholds are as follows: Strongly Undervalued below -18.99, Undervalued between -18.99 and -14.90, Fairly Valued between -6.71 and -14.90, Overvalued between -6.71 and -2.61, and Strongly Overvalued above -2.61. The current Forward P/OCF of -11.50 falls within the Historic Trend Line -Fairly Valued range.

-11.21

P/FCF

Enliven Therapeutics Inc. (ELVN) has a current P/FCF of -11.21. The 5-year average P/FCF is -5.07. The thresholds are as follows: Strongly Undervalued below -17.88, Undervalued between -17.88 and -11.47, Fairly Valued between 1.33 and -11.47, Overvalued between 1.33 and 7.74, and Strongly Overvalued above 7.74. The current Forward P/FCF of -11.21 falls within the Historic Trend Line -Fairly Valued range.

Enliven Therapeutics Inc (ELVN) has a current Price-to-Book (P/B) ratio of 2.09. Compared to its 3-year average P/B ratio of 2.70 , the current P/B ratio is approximately -22.52% higher. Relative to its 5-year average P/B ratio of 2.70, the current P/B ratio is about -22.52% higher. Enliven Therapeutics Inc (ELVN) has a Forward Free Cash Flow (FCF) yield of approximately -7.18%. Compared to its 3-year average FCF yield of -7.03%, the current FCF yield is approximately 2.04% lower. Relative to its 5-year average FCF yield of -7.03% , the current FCF yield is about 2.04% lower.

2.09

P/B

Median3y

2.70

Median5y

2.70

-7.18

FCF Yield

Median3y

-7.03

Median5y

-7.03

Competitors Valuation Multiple

The average P/S ratio for ELVN's competitors is 20102.77, providing a benchmark for relative valuation. Enliven Therapeutics Inc Corp (ELVN) exhibits a P/S ratio of 120553.71, which is 499.69% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ELVN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ELVN in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Enliven Therapeutics Inc (ELVN) currently overvalued or undervalued?

What is Enliven Therapeutics Inc (ELVN) fair value?

ELVN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Enliven Therapeutics Inc (ELVN) is between 6.58 to 21.26 according to relative valuation methord.

How does ELVN's valuation metrics compare to the industry average?

What is the current P/B ratio for Enliven Therapeutics Inc (ELVN) as of Dec 15 2025?

As of Dec 15 2025, Enliven Therapeutics Inc (ELVN) has a P/B ratio of 2.09. This indicates that the market values ELVN at 2.09 times its book value.

What is the current FCF Yield for Enliven Therapeutics Inc (ELVN) as of Dec 15 2025?

As of Dec 15 2025, Enliven Therapeutics Inc (ELVN) has a FCF Yield of -7.18%. This means that for every dollar of Enliven Therapeutics Inc’s market capitalization, the company generates -7.18 cents in free cash flow.

What is the current Forward P/E ratio for Enliven Therapeutics Inc (ELVN) as of Dec 15 2025?

As of Dec 15 2025, Enliven Therapeutics Inc (ELVN) has a Forward P/E ratio of -9.59. This means the market is willing to pay $-9.59 for every dollar of Enliven Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Enliven Therapeutics Inc (ELVN) as of Dec 15 2025?

As of Dec 15 2025, Enliven Therapeutics Inc (ELVN) has a Forward P/S ratio of 120553.71. This means the market is valuing ELVN at $120553.71 for every dollar of expected revenue over the next 12 months.

ELVN Valuation